Epitopea has ordered £ 10m in funding for cancer research technology

Startup company Medech Epitopea has raised $ 13.6m (£ 10.3m) in seed funding from transatlantic syndicates including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital (CIC) and Fonds de solidarité FTQ.

Epitopea will use the seed investment to build its executive team, to further research tumor-specific antigens and to catalyze their translation into new cancer immunotherapy.

Cambridge-based Epitopea is developing cancer immunotherapies by developing a new class of antigens that are shared between patients with the same cancer symptoms.

“With this significant seed funding from a syndicate of top Canadian and UK investors, we can begin to translate these discoveries into new therapy. We will be science-led, using the best modalities available to help cancer patients achieve lasting benefits, ”said Dr Jon Moore, CEO, Epitopea and operating partner at Advent Life Sciences.

Founded in 2021 by Dr. Claude Perreault and Dr. Pierre Thibault, Epitopea is comprised of two sister companies in Cambridge, UK and Montreal, Canada.

Epitopea is one of Cambridge Innovation Capital’s first recipients £ 225m raised a fund to invest in Cambridge-based deep technology and feed start-ups.

Cambridge Innovation Capital has invested in a quantum computer software company River Lane.

Additional funding came from Novateur Ventures and Harrington Discovery Institute / University Health Holdings.

“CTI is delighted to lead the Epitopea seed round, which is the first investment from the third fund, CTI LSF III. We are convinced that Epitopea has the potential to fundamentally change the paradigm of how cancer patients can be treated with therapeutic vaccines and other immunosuppressive therapies to significantly improve their quality of life, ”said Dr Laurence Rulleau , partner, CTI Life Sciences.

In February a competition backed by the NHS they were awarded eight recent innovation projects total funding of £ 9m for the development of cancer diagnosis technologies.

Epitopea has ordered £ 10m in funding for cancer research technology

Source link Epitopea has ordered £ 10m in funding for cancer research technology

Exit mobile version